Iradimed Corp (NASDAQ:IRMD) Holdings Lowered by Victory Capital Management Inc.

Victory Capital Management Inc. trimmed its stake in shares of Iradimed Corp (NASDAQ:IRMD) by 63.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,751 shares of the medical equipment provider’s stock after selling 4,780 shares during the period. Victory Capital Management Inc.’s holdings in Iradimed were worth $56,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Marshall Wace LLP lifted its holdings in shares of Iradimed by 765.6% during the second quarter. Marshall Wace LLP now owns 74,416 shares of the medical equipment provider’s stock valued at $1,522,000 after purchasing an additional 65,819 shares during the last quarter. Morgan Stanley lifted its holdings in shares of Iradimed by 14.3% during the second quarter. Morgan Stanley now owns 13,118 shares of the medical equipment provider’s stock valued at $268,000 after purchasing an additional 1,637 shares during the last quarter. AQR Capital Management LLC lifted its holdings in shares of Iradimed by 52.1% during the second quarter. AQR Capital Management LLC now owns 23,971 shares of the medical equipment provider’s stock valued at $490,000 after purchasing an additional 8,207 shares during the last quarter. Vanguard Group Inc. raised its position in Iradimed by 2.5% during the second quarter. Vanguard Group Inc. now owns 276,203 shares of the medical equipment provider’s stock valued at $5,649,000 after buying an additional 6,658 shares during the period. Finally, BlackRock Inc. raised its position in Iradimed by 14.4% during the second quarter. BlackRock Inc. now owns 390,592 shares of the medical equipment provider’s stock valued at $7,988,000 after buying an additional 49,042 shares during the period. 30.33% of the stock is owned by institutional investors and hedge funds.

Several research firms recently weighed in on IRMD. Zacks Investment Research lowered Iradimed from a “buy” rating to a “hold” rating in a research report on Wednesday, July 3rd. ValuEngine raised Iradimed from a “sell” rating to a “hold” rating in a research report on Wednesday, July 31st.

In related news, insider Louis S. Waldman sold 25,000 shares of the company’s stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $22.71, for a total transaction of $567,750.00. Following the transaction, the insider now directly owns 2,005 shares of the company’s stock, valued at $45,533.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Brent Johnson sold 1,300 shares of the company’s stock in a transaction on Friday, October 11th. The shares were sold at an average price of $21.63, for a total value of $28,119.00. Following the transaction, the vice president now directly owns 2,368 shares in the company, valued at $51,219.84. The disclosure for this sale can be found here. Insiders have sold 85,913 shares of company stock worth $1,907,290 over the last three months. 56.80% of the stock is owned by insiders.

NASDAQ:IRMD opened at $21.68 on Friday. The firm has a market capitalization of $247.51 million, a price-to-earnings ratio of 50.42 and a beta of 1.56. Iradimed Corp has a 1-year low of $16.68 and a 1-year high of $30.90. The company has a current ratio of 10.29, a quick ratio of 9.39 and a debt-to-equity ratio of 0.06. The business’s fifty day moving average price is $20.91 and its 200 day moving average price is $22.16.

Iradimed (NASDAQ:IRMD) last posted its quarterly earnings results on Tuesday, July 30th. The medical equipment provider reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.05. The firm had revenue of $9.23 million for the quarter, compared to analyst estimates of $8.91 million. Iradimed had a return on equity of 14.78% and a net margin of 23.92%. Equities analysts forecast that Iradimed Corp will post 0.67 earnings per share for the current year.

About Iradimed

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system.

Recommended Story: How to calculate the intrinsic value of a stock

Want to see what other hedge funds are holding IRMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iradimed Corp (NASDAQ:IRMD).

Institutional Ownership by Quarter for Iradimed (NASDAQ:IRMD)

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.